易明医药拟6.62亿元易主58同城姚劲波，原实控人设下双重业绩承诺

Core Viewpoint - The control of Yiming Pharmaceutical (002826.SZ) is changing hands from its founder Gao Fan to Beijing Fuhai, with the new actual controller being Yao Jinbo, marking a significant shift in the company's ownership structure [2][3][8]. Group 1: Ownership Change - Gao Fan signed a share transfer agreement to sell 23% of his shares to Beijing Fuhai at a price of 15.10 yuan per share, totaling 662 million yuan [2]. - Following the announcement, Yiming Pharmaceutical's stock resumed trading and hit the daily limit up, opening at 13.40 yuan per share [2]. - The new controller, Yao Jinbo, is also the chairman and CEO of 58.com and holds a significant stake in Kuaigou Dache [3][4]. Group 2: Financial Commitments - The share transfer agreement includes performance commitments, with a revenue target of no less than 600 million yuan annually from 2025 to 2027, and a net profit target of at least 30 million yuan for the same period [8]. - If performance targets are not met, Gao Fan will provide compensation based on specific conditions outlined in the agreement [8]. Group 3: Company Performance - Yiming Pharmaceutical's revenue for 2022, 2023, and projected 2024 are 857 million yuan, 667 million yuan, and 652 million yuan respectively, with net profits of 44 million yuan, 15 million yuan, and 46 million yuan [9]. - The company has shown a decline in revenue and profitability, with a significant reliance on its diabetes drug, Miglitol, which generated 474 million yuan in 2024, accounting for 72.72% of total revenue [9]. - The cardiovascular product, Guo Loupian injection, has seen a drastic revenue drop of 55.61% in 2024, leading to the termination of its partnership with Shanghai Pharmaceutical Group [9][10].